2 weeks Ago By Defense World Staff
Corebridge Financial Inc. decreased its stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 7.
0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,839 shares of the company’s stock after selling 1,422 shares during the quarter. Corebridge Financial Inc.
’s holdings in Apogee Therapeutics were worth $853,000 at the end of the most recent quarter. Other hedge funds have also added to or reduced their stakes in the company. Wellington Management Group LLP grew its holdings in shares of Apogee Therapeutics by 35.
7% during the third quarter. Wellington Management Group LLP now owns 4,814,400 shares of the company’s stock valued at $282,798,000 after buying an additional 1,267,451 shares during the last quarter. Janus Henderson Group PLC lifted its position in Apogee Therapeutics by 4,018.
9% in the 3rd quarter. Janus Henderson Group PLC now owns 469,557 shares of the company’s stock valued at $27,586,000 after acquiring an additional 458,157 shares in the last quarter. Barclays PLC boosted its stake in Apogee Therapeutics by 369.
2% during the 3rd quarter. Barclays PLC now owns 365,046 shares of the company’s stock valued at $21,443,000 after purchasing an additional 287,243 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Apogee Therapeutics by 11.
2% in the 3rd quarter. Geode Capital Management LLC now owns 823,839 shares of the company’s stock worth $48,401,000 after purchasing an additional 82,978 shares in the last quarter. Finally, Charles Schwab Investment Management Inc.
raised its stake in shares of Apogee Therapeutics by 17.5% in the third quarter. Charles Schwab Investment Management Inc.
now owns 280,428 shares of the company’s stock worth $16,472,000 after purchasing an additional 41,686 shares during the last quarter. 79.04% of the stock is owned by institutional investors.
Apogee Therapeutics Stock Down 7.6 %Apogee Therapeutics stock opened at $32.32 on Friday.
Apogee Therapeutics, Inc. has a 52-week low of $29.10 and a 52-week high of $63.
50. The company has a market cap of $1.46 billion, a P/E ratio of -13.
36 and a beta of 1.72. The business has a 50-day simple moving average of $37.
21 and a two-hundred day simple moving average of $45.45. Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last announced its earnings results on Monday, March 3rd.
The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.
25). Research analysts anticipate that Apogee Therapeutics, Inc. will post -3.
09 EPS for the current fiscal year. Insider Transactions at Apogee TherapeuticsIn other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $48.
85, for a total value of $732,750.00. Following the completion of the transaction, the chief executive officer now directly owns 1,309,487 shares in the company, valued at $63,968,439.
95. This represents a 1.13 % decrease in their ownership of the stock.
The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Carl Dambkowski sold 3,520 shares of the firm’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $40.
69, for a total transaction of $143,228.80. Following the sale, the insider now owns 252,623 shares in the company, valued at $10,279,229.
87. The trade was a 1.37 % decrease in their ownership of the stock.
The disclosure for this sale can be found here. Insiders sold 48,970 shares of company stock worth $1,974,451 in the last three months. Corporate insiders own 36.
10% of the company’s stock. Wall Street Analysts Forecast GrowthSeveral equities research analysts recently commented on the company. Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a research report on Monday, February 10th.
Citigroup started coverage on shares of Apogee Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $95.00 target price on the stock.
Finally, Wedbush reiterated an “outperform” rating and issued a $90.00 price target on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Apogee Therapeutics currently has a consensus rating of “Buy” and an average price target of $92.
17.View Our Latest Analysis on APGEAbout Apogee Therapeutics (Free Report)Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Featured StoriesFive stocks we like better than Apogee TherapeuticsUtilities Stocks Explained – How and Why to Invest in UtilitiesConagra Stock Could Thrive as Tariffs Hit Other SectorsWhat is a Bond Market Holiday? How to Invest and TradeGrocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey FindsESG Stocks, What Investors Should KnowSpotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?Want to see what other hedge funds are holding APGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report).
.
